M
Monopar Therapeutics Inc. (MNPR)
NCM – Real Time Price. Currency in USD
61.35
-4.17 (-6.36%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
61.35
-4.17 (-6.36%)
At close: May 12, 2026, 4:00 PM EDT
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Name | Position |
|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. | Co-Founder, CEO, President & Director |
| Dr. Christopher M. Starr Ph.D. | Co-Founder & Independent Executive Chairman of the Board |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer |
| Mr. Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer |
| Ms. Susan Rodriguez |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | mnpr20260330_def14a.htm |
| 2026-04-20 | 8-K | mnpr20260419_8k.htm |
| 2026-04-01 | 10-K/A | mnpr20251231c_10ka.htm |
| 2026-03-27 | 10-K | mnpr20251231_10k.htm |
| 2026-03-02 | 8-K | mnpr20260302_8k.htm |
| 2025-11-13 | 8-K | mnpr20251105_8k.htm |
| 2025-11-10 | 8-K | mnpr20251108_8k.htm |
| 2025-09-24 | 8-K | mnpr20250924_8k.htm |
| 2025-09-15 | 8-K | mnpr20250912_8k.htm |
| 2025-09-05 | CORRESP | filename1.htm |
| Chief Commercial & Strategy Officer |